Combined administration of cysteine-aspartic protease inhibitors with P2Y12 receptor antagonists protects the heart against myocardial infarction
The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y 12 receptor antagonist or Glycoprotein IIb/IIIa inhibitor, the cysteine-aspartic protease inhibitor is selected from the group consisting of Caspase-1, 4, 5, 11 and 12 inhibitors, and reperfusion therapy is percutaneous coronary intervention. In certain embodiments, the at least one P2Y 12 receptor antagonist is selected from the group consisting of cangrelor, ticagrelor, clopidogrel and prasugrel. The disclosed methods provide an improved cardioprotective effect against infarction when compared with the current standard of care.
1. A method of treating infarct in a subj ect in need thereof comprising the steps of:
administering a P2Y 12 receptor antagonist, wherein the P2Y12 receptor antagonist is cangrelor;
administering a cysteine-aspartic protease inhibitor, wherein the cysteine-aspartic protease inhibitor is (S)-1((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765); and
administering reperfusion therapy.
2. The method of claim 1 , wherein the reperfusion therapy comprises percutaneous coronary intervention.
3. The method of claim 1 , wherein the reperfusion therapy is administered after administration of cangrelor and VX-765.
4. The method of claim 1 , wherein the cangrelor and VX-76 are co-administered.